Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Our research addressing the molecular basis of dementia in AD has involved the creation of Aβ and tau transgenic mice. Our work and that of other investigators has shown that plaques and tangles do not cause cognitive deficits in mice. These exciting findings have redirected research away from the structural consequences of the Aβ and tau peptides and turned attention toward studies of their functional consequences. We refer to the specific species of Aβ and tau that underlie memory deficits as Aβ star (Aβ*) and tau star (tau*) (see Figure 1). Aβ* and tau* are potential early causative agents in AD. Investigations of Aβ* and tau* have been made possible by the creation and study of memory and cognitive function in transgenic mice and in non-transgenic rat models of Alzheimer's disease. Identifying Aβ* and tau* is the most logical first step to developing therapies to modulate Aβ-and tau-related brain dysfunction. Successful approaches to the prevention and treatment of AD will depend upon isolating Aβ* and tau* and understanding the cellular mechanisms by which they disrupt brain function.

Original languageEnglish (US)
Title of host publicationAlzheimer's Disease
Subtitle of host publicationAdvances in Genetics, Molecular and Cellular Biology
PublisherSpringer US
Pages77-91
Number of pages15
ISBN (Print)0387351345, 9780387351346
DOIs
StatePublished - Dec 1 2007

Fingerprint

Transgenic Mice
Alzheimer Disease
Memory Disorders
Brain
Research
Cognition
Dementia
Research Personnel
Peptides
Therapeutics
Cognitive Dysfunction

Cite this

Ashe, K. H. (2007). Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease. In Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology (pp. 77-91). Springer US. https://doi.org/10.1007/978-0-387-35135-3_5

Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease. / Ashe, Karen H.

Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. Springer US, 2007. p. 77-91.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ashe, KH 2007, Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease. in Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. Springer US, pp. 77-91. https://doi.org/10.1007/978-0-387-35135-3_5
Ashe KH. Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease. In Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. Springer US. 2007. p. 77-91 https://doi.org/10.1007/978-0-387-35135-3_5
Ashe, Karen H. / Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease. Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. Springer US, 2007. pp. 77-91
@inbook{6a7ca80df48e424e9cfb75953e830a43,
title = "Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease",
abstract = "Our research addressing the molecular basis of dementia in AD has involved the creation of Aβ and tau transgenic mice. Our work and that of other investigators has shown that plaques and tangles do not cause cognitive deficits in mice. These exciting findings have redirected research away from the structural consequences of the Aβ and tau peptides and turned attention toward studies of their functional consequences. We refer to the specific species of Aβ and tau that underlie memory deficits as Aβ star (Aβ*) and tau star (tau*) (see Figure 1). Aβ* and tau* are potential early causative agents in AD. Investigations of Aβ* and tau* have been made possible by the creation and study of memory and cognitive function in transgenic mice and in non-transgenic rat models of Alzheimer's disease. Identifying Aβ* and tau* is the most logical first step to developing therapies to modulate Aβ-and tau-related brain dysfunction. Successful approaches to the prevention and treatment of AD will depend upon isolating Aβ* and tau* and understanding the cellular mechanisms by which they disrupt brain function.",
author = "Ashe, {Karen H}",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/978-0-387-35135-3_5",
language = "English (US)",
isbn = "0387351345",
pages = "77--91",
booktitle = "Alzheimer's Disease",
publisher = "Springer US",

}

TY - CHAP

T1 - Cognitive impairment in transgenic Aβ and tau models of alzheimer's disease

AU - Ashe, Karen H

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Our research addressing the molecular basis of dementia in AD has involved the creation of Aβ and tau transgenic mice. Our work and that of other investigators has shown that plaques and tangles do not cause cognitive deficits in mice. These exciting findings have redirected research away from the structural consequences of the Aβ and tau peptides and turned attention toward studies of their functional consequences. We refer to the specific species of Aβ and tau that underlie memory deficits as Aβ star (Aβ*) and tau star (tau*) (see Figure 1). Aβ* and tau* are potential early causative agents in AD. Investigations of Aβ* and tau* have been made possible by the creation and study of memory and cognitive function in transgenic mice and in non-transgenic rat models of Alzheimer's disease. Identifying Aβ* and tau* is the most logical first step to developing therapies to modulate Aβ-and tau-related brain dysfunction. Successful approaches to the prevention and treatment of AD will depend upon isolating Aβ* and tau* and understanding the cellular mechanisms by which they disrupt brain function.

AB - Our research addressing the molecular basis of dementia in AD has involved the creation of Aβ and tau transgenic mice. Our work and that of other investigators has shown that plaques and tangles do not cause cognitive deficits in mice. These exciting findings have redirected research away from the structural consequences of the Aβ and tau peptides and turned attention toward studies of their functional consequences. We refer to the specific species of Aβ and tau that underlie memory deficits as Aβ star (Aβ*) and tau star (tau*) (see Figure 1). Aβ* and tau* are potential early causative agents in AD. Investigations of Aβ* and tau* have been made possible by the creation and study of memory and cognitive function in transgenic mice and in non-transgenic rat models of Alzheimer's disease. Identifying Aβ* and tau* is the most logical first step to developing therapies to modulate Aβ-and tau-related brain dysfunction. Successful approaches to the prevention and treatment of AD will depend upon isolating Aβ* and tau* and understanding the cellular mechanisms by which they disrupt brain function.

UR - http://www.scopus.com/inward/record.url?scp=35349026979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349026979&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-35135-3_5

DO - 10.1007/978-0-387-35135-3_5

M3 - Chapter

AN - SCOPUS:35349026979

SN - 0387351345

SN - 9780387351346

SP - 77

EP - 91

BT - Alzheimer's Disease

PB - Springer US

ER -